Background
Dengue is one of India's fastest-growing vector-borne diseases, with frequent outbreaks during the monsoon season.
India has witnessed a steady rise in dengue cases due to rapid urbanisation, climate change, water stagnation, and expansion of mosquito breeding habitats.
Until now, dengue prevention in India primarily relied on vector control, surveillance, public awareness, and supportive treatment, as no licensed vaccine was available.
QDENGA is the first dengue vaccine to receive regulatory approval in India, offering a new preventive tool alongside existing public health measures.
Features of QDENGA (TAK-003)
Type: Live attenuated tetravalent vaccine.
Target Group: Individuals aged 4–60 years.
Coverage: Protects against all four dengue virus serotypes (DENV-1, DENV-2, DENV-3, DENV-4).
Dosage: Two doses administered 3 months apart.
Universal Use: Can be administered irrespective of previous dengue infection.
No Pre-vaccination Screening: Unlike some earlier dengue vaccines, no prior antibody testing is required.
Clinical Evidence:
Evaluated in 19 Phase I, II and III clinical trials involving over 28,000 participants.
80.2% efficacy against confirmed dengue (12 months after second dose).
90.4% efficacy against dengue-related hospitalisation (18 months).
Protection sustained for up to 7 years in long-term follow-up.
Global Recognition:
Approved in 43 countries.
WHO prequalified and recommended for areas with high dengue transmission.
Included in national immunisation programmes of Brazil and public programmes in Argentina, Colombia, and Indonesia.
Challenges
High Cost: Affordability may limit widespread access without government support.
Limited Availability: Initial production and supply constraints may delay large-scale rollout.
Not a Standalone Solution: Vaccination cannot replace mosquito control and environmental sanitation.
Awareness Gap: Vaccine hesitancy and lack of public awareness may affect uptake.
Implementation Challenges: Integrating the vaccine into existing immunisation programmes requires adequate logistics, cold-chain infrastructure, and trained healthcare workers.
Surveillance Needs: Continuous monitoring for vaccine effectiveness and adverse events is essential
Way Forward
Integrate the vaccine into a phased national dengue control strategy, prioritising high-burden states.
Continue strengthening vector control measures, including elimination of mosquito breeding sites and community participation.
Enhance disease surveillance and early outbreak detection through integrated health information systems.
Conduct public awareness campaigns on vaccination, personal protection, and environmental hygiene.
Ensure affordable pricing and equitable access through government procurement and public immunisation programmes.
Promote research and genomic surveillance to monitor circulating dengue serotypes and vaccine effectiveness.
Conclusion
The approval of QDENGA marks a significant advancement in India's fight against dengue by providing the country's first licensed vaccine against all four dengue virus serotypes. However, vaccination should complement-not replace-vector control, surveillance, and public health awareness. A comprehensive, integrated approach will be essential to reduce dengue-related illness, hospitalisations, and deaths.
